[go: up one dir, main page]

WO2007124757A3 - Use of escitalopram for improving cognition - Google Patents

Use of escitalopram for improving cognition Download PDF

Info

Publication number
WO2007124757A3
WO2007124757A3 PCT/DK2007/050050 DK2007050050W WO2007124757A3 WO 2007124757 A3 WO2007124757 A3 WO 2007124757A3 DK 2007050050 W DK2007050050 W DK 2007050050W WO 2007124757 A3 WO2007124757 A3 WO 2007124757A3
Authority
WO
WIPO (PCT)
Prior art keywords
escitalopram
improving cognition
cognition
improving
isobenzofurancarbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2007/050050
Other languages
French (fr)
Other versions
WO2007124757A2 (en
Inventor
Hans Torgny Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07722705A priority Critical patent/EP2026793A2/en
Priority to AU2007245983A priority patent/AU2007245983A1/en
Priority to BRPI0710230-5A priority patent/BRPI0710230A2/en
Priority to EA200870491A priority patent/EA200870491A1/en
Priority to MX2008013911A priority patent/MX2008013911A/en
Priority to JP2009508134A priority patent/JP2009535367A/en
Priority to CA002651002A priority patent/CA2651002A1/en
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of WO2007124757A2 publication Critical patent/WO2007124757A2/en
Publication of WO2007124757A3 publication Critical patent/WO2007124757A3/en
Priority to IL194628A priority patent/IL194628A0/en
Priority to ZA2008/08632A priority patent/ZA200808632B/en
Anticipated expiration legal-status Critical
Priority to NO20085009A priority patent/NO20085009L/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of the compound escitalopram (INN-name), i.e. (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5- isobenzofurancarbonitrile, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
PCT/DK2007/050050 2006-05-02 2007-04-30 Use of escitalopram for improving cognition Ceased WO2007124757A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002651002A CA2651002A1 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition
BRPI0710230-5A BRPI0710230A2 (en) 2006-05-02 2007-04-30 use of escitalopram or a pharmaceutically acceptable salt of the same use of escitalopram or a pharmaceutically acceptable salt thereof in combination with one or more antipsychotic compounds, pharmaceutical composition, method for improving cognition in a condition where the cognitive process is impaired, and use of escitalopram
EA200870491A EA200870491A1 (en) 2006-05-02 2007-04-30 NEW USE OF ESCITAL PREMA
MX2008013911A MX2008013911A (en) 2006-05-02 2007-04-30 New uses of escitalopram.
JP2009508134A JP2009535367A (en) 2006-05-02 2007-04-30 Use of escitalopram to improve cognition
EP07722705A EP2026793A2 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition
AU2007245983A AU2007245983A1 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition
IL194628A IL194628A0 (en) 2006-05-02 2008-10-07 Use of escitalopram for improving cognition
ZA2008/08632A ZA200808632B (en) 2006-05-02 2008-10-09 Use of escitalopram for improving cognition
NO20085009A NO20085009L (en) 2006-05-02 2008-12-02 New uses of escitalopram

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600621 2006-05-02
DKPA200600621 2006-05-02

Publications (2)

Publication Number Publication Date
WO2007124757A2 WO2007124757A2 (en) 2007-11-08
WO2007124757A3 true WO2007124757A3 (en) 2008-07-24

Family

ID=38134951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2007/050050 Ceased WO2007124757A2 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition

Country Status (15)

Country Link
EP (1) EP2026793A2 (en)
JP (1) JP2009535367A (en)
KR (1) KR20090009820A (en)
CN (1) CN101426494A (en)
AR (1) AR060732A1 (en)
AU (1) AU2007245983A1 (en)
BR (1) BRPI0710230A2 (en)
CA (1) CA2651002A1 (en)
EA (1) EA200870491A1 (en)
IL (1) IL194628A0 (en)
MX (1) MX2008013911A (en)
NO (1) NO20085009L (en)
TW (1) TW200812993A (en)
WO (1) WO2007124757A2 (en)
ZA (1) ZA200808632B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257589A1 (en) 2002-08-22 2004-03-11 Sumitomo Pharmaceuticals Company, Limited Remedy for integration dysfunction syndrome
AU2004249621B2 (en) 2003-06-23 2009-08-06 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
WO2005080976A1 (en) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Method of in vivo screening of therapeutic agent for memory/learning dysfunction by schizophrenia
AU2008283989B2 (en) * 2007-08-03 2013-12-05 Richter Gedeon Nyrt. Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands.
EP2236138A1 (en) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
US8258139B2 (en) * 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
EP3069718A1 (en) * 2015-03-17 2016-09-21 Universidade do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
KR102506333B1 (en) 2016-12-20 2023-03-06 에르테에스 로만 테라피-시스테메 아게 Transdermal absorption treatment system containing asenapine
CN110087641B (en) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 Transdermal therapeutic systems containing asenapine and polysiloxane or polyisobutylene
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CN112704672A (en) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
CN112533593A (en) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
KR102051624B1 (en) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 Pharmaceutical composition for treatment of neurodegenerative brain disease comprising triflupromazine or pharmacurically acceptable salt thereof as an active ingredient
CN109464436A (en) * 2019-01-10 2019-03-15 高智玉 Citalopram or escitalopram combine the application in the compound preparation of preparation treatment phrenoblabia class disease with Quetiapine respectively

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474580A2 (en) * 1990-09-06 1992-03-11 H. Lundbeck A/S Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders
WO2000015219A1 (en) * 1998-09-16 2000-03-23 Astrazeneca Ab A new composition
WO2000015220A1 (en) * 1998-09-16 2000-03-23 Astrazeneca Ab A new composition
WO2002043764A1 (en) * 2000-12-01 2002-06-06 Be Able, Llc Behavior chemotherapy
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
WO2003041563A2 (en) * 2001-11-13 2003-05-22 Be Able, Llc Neurotransmitter balance chemotherapy
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
WO2004056791A1 (en) * 2002-12-23 2004-07-08 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
US20050014848A1 (en) * 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
WO2005023243A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and loxapine
WO2007048080A2 (en) * 2005-10-14 2007-04-26 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
WO2007053796A2 (en) * 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
WO2007070840A2 (en) * 2005-12-14 2007-06-21 H. Lundbck A/S. Modified and pulsatile release pharmaceutical formulations of escitalopram

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474580A2 (en) * 1990-09-06 1992-03-11 H. Lundbeck A/S Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders
WO2000015219A1 (en) * 1998-09-16 2000-03-23 Astrazeneca Ab A new composition
WO2000015220A1 (en) * 1998-09-16 2000-03-23 Astrazeneca Ab A new composition
WO2002043764A1 (en) * 2000-12-01 2002-06-06 Be Able, Llc Behavior chemotherapy
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
WO2003041563A2 (en) * 2001-11-13 2003-05-22 Be Able, Llc Neurotransmitter balance chemotherapy
US20050014848A1 (en) * 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
WO2004056791A1 (en) * 2002-12-23 2004-07-08 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
WO2005023243A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and loxapine
WO2007048080A2 (en) * 2005-10-14 2007-04-26 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
WO2007053796A2 (en) * 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
WO2007070840A2 (en) * 2005-12-14 2007-06-21 H. Lundbck A/S. Modified and pulsatile release pharmaceutical formulations of escitalopram

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ANGELONE S M ET AL: "Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics.", ALCOHOL AND ALCOHOLISM (OXFORD, OXFORDSHIRE) 1998 MAR-APR, vol. 33, no. 2, March 1998 (1998-03-01), pages 151 - 156, XP002481209, ISSN: 0735-0414 *
ARCHIVES OF GENERAL PSYCHIATRY FEB 2004, vol. 61, no. 2, February 2004 (2004-02-01), pages 152 - 159, ISSN: 0003-990X *
BAUMANN PIERRE ET AL: "Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram.", EUROPEAN NEUROPSYCHOPHARMACOLOGY : THE JOURNAL OF THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY OCT 2002, vol. 12, no. 5, October 2002 (2002-10-01), pages 433 - 444, XP002481210, ISSN: 0924-977X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 2005 (2005-06-01), FRIEDMAN JOSEPH I ET AL: "The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia", XP002481217, Database accession no. PREV200510070715 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DAVIDS, EUGEN ET AL: "Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats", XP002481212, retrieved from STN Database accession no. 2002:435038 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FEDOTOVA, YU. O. ET AL: "Cypramil correction of passive avoidance performance in ovariectomized female rats", XP002481216, retrieved from STN Database accession no. 2003:207883 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 2003, SVESTKA J: "Escitalopram - The selective stereoisomer of citalopram", XP002481218, Database accession no. EMB-2003157849 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1999 (1999-12-01), CALANDRA C ET AL: "The use of citalopram in an integrated approach to the treatment of eating disorders: an open study.", XP002481215, Database accession no. NLM10728184 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2004 (2004-02-01), STEIN MICHAEL D ET AL: "Pharmacotherapy plus psychotherapy for treatment of depression in active injection drug users.", XP002481213, Database accession no. NLM14757591 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; October 2001 (2001-10-01), ALEXOPOULOS G S ET AL: "The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients.", XP002481214, Database accession no. NLM17205639 *
EATING AND WEIGHT DISORDERS : EWD DEC 1999, vol. 4, no. 4, December 1999 (1999-12-01), pages 207 - 210, ISSN: 1124-4909 *
EKSPERIMENTAL'NAYA I KLINICHESKAYA FARMAKOLOGIYA , 66(1), 8-11 CODEN: EKFAE9; ISSN: 0869-2092, 2003 *
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 25, no. 3, June 2005 (2005-06-01), pages 237 - 242, ISSN: 0271-0749 *
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS , 301(3), 1097-1102 CODEN: JPETAB; ISSN: 0022-3565, 2002 *
MONTGOMERY S A ET AL: "ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004.", EUROPEAN NEUROPSYCHOPHARMACOLOGY : THE JOURNAL OF THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY JAN 2007, vol. 17, no. 1, January 2007 (2007-01-01), pages 70 - 77, XP002481211, ISSN: 0924-977X *
POSTGRADUATE MEDICINE OCT 2001, vol. Spec No Pharmacotherapy, October 2001 (2001-10-01), pages 1 - 86, ISSN: 0032-5481 *
PSYCHIATRIE 2003 CZ, vol. 7, no. 1, 2003, pages 38 - 45, ISSN: 1211-7579 *

Also Published As

Publication number Publication date
MX2008013911A (en) 2008-11-12
ZA200808632B (en) 2009-12-30
KR20090009820A (en) 2009-01-23
AU2007245983A1 (en) 2007-11-08
BRPI0710230A2 (en) 2011-08-02
EP2026793A2 (en) 2009-02-25
AR060732A1 (en) 2008-07-10
CA2651002A1 (en) 2007-11-08
CN101426494A (en) 2009-05-06
WO2007124757A2 (en) 2007-11-08
EA200870491A1 (en) 2009-04-28
IL194628A0 (en) 2009-08-03
NO20085009L (en) 2008-12-16
JP2009535367A (en) 2009-10-01
TW200812993A (en) 2008-03-16

Similar Documents

Publication Publication Date Title
WO2007124757A3 (en) Use of escitalopram for improving cognition
WO2008027542A3 (en) 5-substituted isoindoline compounds
ES2195554T3 (en) METHOD FOR THE PREPARATION OF CITALOPRAM.
WO2008081399A3 (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
WO2008072053A3 (en) Substituted arylpyrazoles
WO2007135527A3 (en) Benzimidazolyl compounds
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
EP2291415A4 (en) CATALYSTS FOR THE PREPARATION OF CIS-1,4-POLYDIENES
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
NZ595314A (en) PHARMACEUTICAL COMPOSITIONS comprising (1S)-1,5-anhydro-1-[5-(4-ethoxybenzy1)-2-methoxy-4- methylpheny1]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and metformin.
WO2008017491A8 (en) Ligustilide derivatives for the treatment of disorders of the central nervous system
WO2008136392A1 (en) Preparation for oral administration
WO2007103295A3 (en) Halogenated sulfonamide derivatives
WO2006124861A3 (en) Benzofuran compounds
WO2010049449A3 (en) Novel salts of sunitinib
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2008059514A3 (en) Process for preparing escitalopram
WO2009013010A3 (en) 5ht6-ligands such as sulfonamide derivatives in drug- induced weight-gain
WO2008104880A3 (en) Stable solid dosage forms of an antidepressant
WO2008126106A8 (en) Novel and improved processes for the preparation of intermediates of darifenacin, darifenacin and its pharmaceutically acceptable salts
WO2006077024A3 (en) 5-aminoindole derivatives
EP2366393A3 (en) Roflumilast for the treatment of pulmonary hypertension
WO2006123243A3 (en) Pharmaceutical dosage forms comprising escitalopram in form of granules
WO2007130890A3 (en) Cyclopentane-derivatives and their use as ocular hypotensive agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07722705

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 571785

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12008502259

Country of ref document: PH

Ref document number: 194628

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020087025797

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200780014675.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/013911

Country of ref document: MX

Ref document number: 2008101785

Country of ref document: EG

Ref document number: 2007245983

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2651002

Country of ref document: CA

Ref document number: 2009508134

Country of ref document: JP

Ref document number: 08116966

Country of ref document: CO

Ref document number: 5930/CHENP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007245983

Country of ref document: AU

Date of ref document: 20070430

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007722705

Country of ref document: EP

Ref document number: 200870491

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0710230

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081020